17744-98-8

Usage

Uses

Used in Pharmaceutical Research and Development:
IMIDAZO[1,2-A]PYRIDIN-3-YL-ACETONITRILE is used as a key intermediate in the synthesis of new drugs and active pharmaceutical ingredients. Its unique molecular structure allows for the development of compounds with potential therapeutic applications in various medical fields.
Used in Organic Synthesis:
In the field of organic synthesis, IMIDAZO[1,2-A]PYRIDIN-3-YL-ACETONITRILE serves as an important building block for the creation of various chemical compounds. Its versatile structure enables the synthesis of a wide range of molecules with diverse properties and applications.
Used in Drug Development:
IMIDAZO[1,2-A]PYRIDIN-3-YL-ACETONITRILE is used as a starting material in the development of new drugs. Its potential applications in the pharmaceutical industry make it a valuable compound for researchers working on the discovery and optimization of novel therapeutic agents.
Used in Chemical Compound Production:
As an intermediate in the production of various chemical compounds, IMIDAZO[1,2-A]PYRIDIN-3-YL-ACETONITRILE plays a crucial role in the synthesis of a multitude of molecules with different applications across various industries. Its presence in the synthesis process contributes to the creation of innovative and useful products.

InChI:InChI=1/C9H7N3/c10-5-4-8-7-11-9-3-1-2-6-12(8)9/h1-3,6-7H,4H2

Upstream product

• 2717-95-5 1-(imidazo[1,2-a]pyridin-3-yl)-N,N-dimethylmethanamine 
• 274-76-0 imidazo[1,2-a]pyridine 
• 50-00-0 formaldehyd 
• 504-29-0 2-aminopyridine 
• 773837-37-9 sodium cyanide 

Downstream Products

• 1312891-90-9 (E)-3-(4-{[2-(imidazo[1,2-a]pyridin-3-yl)ethylamino]methyl}phenyl)acrylic acid methyl ester 
• 1312891-52-3 (E)-N-hydroxy-3-(4-{[2-(imidazo[1,2-a]pyridin-3-yl)ethylamino]methyl}phenyl)acrylamide 
• 664367-52-6 2-(imidazo[1,2-a]pyridin-3-yl)ethylamine 
• 17745-04-9 imidazo<1,2-a>pyridin-3-acetic acid 
• 950888-59-2 C₉H₁₅N₃ 

Relevant academic research and scientific papers

INDOLE AHR INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

New fluorescent heterocyclic systems from imidazo[1,2-a]pyridine: Design, synthesis, spectral studies and quantum-chemical investigations

Two new fluorescent heterocyclic systems dipyrido[1′,2′:1,2]imidazo[4,5-b:4,5-e]pyridine-13-carbonitrile and pyrido[1′,2′:1,2]imidazo[4,5-b]pyrido[2′,1′:2,3]imidazo[4,5-e]pyridine-13-carbonitrile were synthesized by one-pot reaction of imidazo[1,2-a]pyridine with 2-(imidazo[1,2-a]pyridin-3-yl)acetonitrile and 2-(imidazo[1,2-a]pyridin-2-yl)acetonitrile, respectively, in MeOH/KOH solution via the nucleophilic substitution of hydrogen in high yields. Spectral and analytical data have confirmed the structures of the synthesized dyes. The optical and solvatochromic properties of the compounds were investigated and the results showed that they exhibited interesting photophysical properties. Density functional theory (DFT) calculations of fluorescent dyes were performed to provide the optimized geometries and relevant frontier orbitals by using the B3LYP hybrid functional and the 6–311?++ G(d,p) basis set. Calculated electronic absorption spectra were also obtained by time-dependent density functional theory (TD-DFT) method. In addition, electron density iso-surface map, intra- and intermolecular interactions of these fluorescent heterocyclic systems were evaluated by AIM (Atoms in Molecules) analysis.

Preparation method of minodronic acid

The invention discloses a preparation method of minodronic acid. The method uses 1-[imidazo(1,2-alpha)pyridine-3-ly]methyl-N,N,N-trimethyliodide and sodium cyanide as raw materials, and comprises the steps of a cyan substitution reaction, a hydrolysis reaction, a phosphorylation reaction and refining. According to the preparation method of minodronic acid provided by the invention, a usage amount of the sodium cyanide is strictly controlled; DMF is used as a solvent, solubility of the raw materials is good, a system is in a homogeneous phase; silicagel columns are used, so that purities with deep colors and large polarities and the ionic compound sodium cyanide can be intercepted, and a nitrile compound, a first midbody, with high purity is acquire, and a basis is established for smoothness of the whole technology.

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors

Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree of pharmacophore homology between these two targets was discovered. This similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.